Source-grounded facts extracted from Guardant Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Guardant Health, Inc. reported the quarter ended March 31, 2026 results: revenue $301.7 million. Guidance raised.
“March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue”
Guardant Health, Inc. incurred convertible notes of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033 with U.S. Bank Trust Company, National Association at 0.00% maturing May 15, 2033.
“On November 7, 2025, the Company completed its previously announced private offering (the “Convertible Notes Offering”) of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033 (the “Notes”), which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $52.5 million principal amount of Notes.”
Roberto Mignone was appointed as Class I Director at Guardant Health, Inc..
“On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.”
Manuel Hidalgo Medina was appointed as Class II Director at Guardant Health, Inc..
“On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.”
Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.
“Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023”
Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.
“Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.